{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-088722","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.963559+00:00","generated_at":"2026-05-31T09:50:26.955706+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zura Bio reports Q2 2024 net loss of $12.7M, cash of $188.4M; plans Phase 2 starts for tibulizumab","bullets":["Net loss of $12.7M ($0.17/share) vs $44.9M ($1.31/share) in Q2 2023; reduction driven by prior-year acquisition costs.","Cash, cash equivalents and investments of $188.4M as of June 30, 2024, including $112.5M from April private placement; sufficient through 2027.","Tibulizumab Phase 2 study in systemic sclerosis expected to start in Q4 2024; Phase 2 in hidradenitis suppurativa expected in Q2 2025.","CEO Robert Lisicki appointed in April 2024; founding CEO Dr. Someit Sidhu remains on Board.","R&D expenses were $5.5M in Q2 2024, down from $28.2M in Q2 2023 due to prior-year tibulizumab acquisition from Lilly."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-088722","json":"https://secwatch.observer/filing/0001104659-24-088722.json","markdown":"https://secwatch.observer/filing/0001104659-24-088722.md","text":"https://secwatch.observer/filing/0001104659-24-088722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924088722/0001104659-24-088722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924088722/tm2411301d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:50:26.955706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}